Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis

BACKGROUND: Nearly 85 % of lung-cancer-specific epidermal growth factor receptor (EGFR) sensitive mutations comprise a substitution at position 858 (21L858R) and deletion mutants in exon 19 (19del). The aim of this study was to assess the role of EGFR mutation subtypes in predicting the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Huan, Huang, Jing, Yu, Xiaojin, Han, Shuhua, Yan, Xing, Sun, Siqing, Zhu, Xiaoli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Review – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196046/
https://www.ncbi.nlm.nih.gov/pubmed/24908327
http://dx.doi.org/10.1007/s00432-014-1709-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196046/
https://www.ncbi.nlm.nih.gov/pubmed/24908327
http://dx.doi.org/10.1007/s00432-014-1709-0

Ejemplares similares